TSVT — 2Seventy Bio Balance Sheet
0.000.00%
- $265.62m
- $95.24m
- $37.86m
- 42
- 27
- 80
- 48
Annual balance sheet for 2Seventy Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | — | 265 | 266 | 217 | 175 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 10.7 | 17 | 21 | 13.4 | 7.78 |
| Prepaid Expenses | |||||
| Total Current Assets | 25.1 | 292 | 301 | 238 | 187 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 260 | 310 | 297 | 278 | 238 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 313 | 760 | 657 | 565 | 480 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 75.9 | 98.4 | 79.8 | 59.8 | 40.1 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 238 | 400 | 346 | 310 | 269 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 74.6 | 360 | 310 | 255 | 211 |
| Total Liabilities & Shareholders' Equity | 313 | 760 | 657 | 565 | 480 |
| Total Common Shares Outstanding |